NYSEAMERICAN : PTHS
Pelthos Therapeutics Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 9.4 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 35.99M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 44.12M |
| Enterprise Value | 93.04M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 3.83M |
| Shares Outstanding | 3.83M |
| Shares Change (YoY) | +435.44% |
| Shares Change (QoQ) | +6.84% |
| Owned by Insiders (%) | 10.01% |
| Owned by Institutions (%) | 26.97% |
| Float | 1.36M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.83 |
| Forward PS | 0.40 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 1.96 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.98 |
| Quick Ratio | 1.21 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -7.46 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -49.98% |
| Return on Invested Capital (ROIC) | -102.45% |
| Return on Capital Employed (ROCE) | -52.42% |
| Weighted Average Cost of Capital (WACC) | 12.40% |
| Revenue Per Employee | $470,696 |
| Profits Per Employee | -$939,043 |
| Employee Count | 92 |
| Asset Turnover | 0.63 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | -7.39M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 3.11 |
| 52-Week Price Change | -66.15% |
| 50-Day Moving Average | 21.07 |
| 200-Day Moving Average | 24.14 |
| Relative Strength Index (RSI) | 29.38 |
| Average Volume (20 Days) | 69,035 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 142,250 |
| Short Previous Month | 93,741 |
| Short % of Shares Out | 3.72% |
| Short % of Float | 10.46% |
| Short Ratio (days to cover) | 3.73 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 43.30M |
| Gross Profit | 32.73M |
| Operating Income | -55.25M |
| Pretax Income | -93.78M |
| Net Income | -86.39M |
| EBITDA | n/a |
| EBIT | -55.25M |
| Loss Per Share | -$26.36 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 24.19M |
| Total Debt | 73.11M |
| Net Cash | -48.92M |
| Net Cash Per Share | -$12.78 |
| Equity (Book Value) | -1.50M |
| Book Value Per Share | -0.40 |
| Working Capital | 31.40M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -42.30M |
| Capital Expenditures | -295,000 |
| Depreciation & Amortization | 1.69M |
| Net Borrowing | 44.64M |
| Free Cash Flow | -42.60M |
| FCF Per Share | -$11.13 |
Margins
| Measure | Value |
|---|
| Gross Margin | 75.58% |
| Operating Margin | -127.60% |
| Pretax Margin | -216.56% |
| Profit Margin | -199.50% |
| EBITDA Margin | n/a |
| EBIT Margin | -127.60% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -435.44% |
| Shareholder Yield | -435.44% |
| Earnings Yield | -228.72% |
| FCF Yield | -118.36% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $49.57 |
| Price Target Difference | 330.11% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | 110.08% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Jul 2, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -1.57 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |